NCT06004921View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
Cancer
Interventions
DRUG

AB801

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (1)

Unknown

Quotient Sciences - Nottingham, Nottingham

Sponsors
All Listed Sponsors
lead

Arcus Biosciences, Inc.

INDUSTRY